Abstract:Vinith Yathindranath, 1, 2 Nura Safa, 1, 2 Mateusz Marek Tomczyk, 1, 3 Vernon Dolinsky, 1, 3 Donald W Miller 1, 2 1 Department of Pharmacology and Therapeutics, University of Manitoba, Winnipeg, MB, Canada; 2 PrairieNeuro Research Centre, Health Science Centre, Winnipeg, MB, Canada; 3 Children's Hospital Research Institute Manitoba, Health Science Centre, Winnipeg, MB, Canada Correspondence: Donald W Miller, Tel +1 204 789 3278, Email Purpose: The global pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and the lingering threat to public health has fueled the search for effective therapeutics to treat SARS-CoV-2. This study aimed to develop lipid nanoparticle (LNP) inhibitors of SARS-CoV-2 entry to reduce viral infection in the nose and upper airway. Methods: Two types of LNP formulations were prepared following a microfluidic mixing method. The LNP-Trap consisted of DOPC, DSPC, cholesterol, and DSPE-PEG-COOH modified with various spike protein binding ligands, including ACE2 peptide, recombinant human ACE2 (rhACE2) or monoclonal antibody to spike protein (mAb). The LNP-Trim consisted of ionizing cationic DLin-MC3-DMA, DSPC, cholesterol, and DMG-PEG lipids encapsulating si ACE2 or si TMPRSS2 . Both formulations were assayed for biocompatibility and cell uptake in airway epithelial cells (Calu-3). Functional assessment of activity was performed using SARS-CoV-2 spike protein binding assays (LNP-Trap), host receptor knockdown (LNP-Trim), and SARS-CoV-2 pseudovirus neutralization assay (LNP-Trap and LNP-Trim). Localization and tissue distribution of fluorescently labeled LNP formulations were assessed in mice following intranasal administration. Results: Both LNP formulations were biocompatible based on cell impedance and MTT cytotoxicity studies in Calu-3 cells at concentrations as high as 1 mg/mL. LNP-Trap formulations were able to bind spike protein and inhibit pseudovirus infection by 90% in Calu-3 cells. LNP-Trim formulations reduced ACE2 and TMPRSS2 at the mRNA (70% reduction) and protein level (50% reduction). The suppression of host targets in Calu-3 cells treated with LNP-Trim resulted in over 90% inhibition of pseudovirus infection. In vivo studies demonstrated substantial retention of LNP-Trap and LNP-Trim in the nasal cavity following nasal administration with minimal systemic exposure. Conclusion: Both LNP-Trap and LNP-Trim formulations were able to safely and effectively inhibit SARS-CoV-2 pseudoviral infection in airway epithelial cells. These studies provide proof-of-principle for a localized treatment approach for SARS-CoV-2 in the upper airway. Keywords: lipid nanoparticles, SARS-CoV-2, antiviral, gene knockdown, intranasal drug delivery Graphical The emergence of a novel SARS-coronavirus-2 (SARS-CoV-2) and the resulting COVID-19 pandemic has had crippling effects on public health and the global economy. Statistics from the World Health Organization (WHO) reported over 758 million confirmed cases of COVID-19 and over 6.8 million related deaths. 1 The COVID-19 and earlier SARS (2002) and Middle East respiratory syndrome (MERS; 2012) outbreaks were caused by closely related coronaviruses (CoV). 2 These viruses use spike proteins to bind and gain entry to specific host cell receptors during infection. While the development of effective vaccines for SARS-CoV-2 has been critical in slowing the spread and limiting mortality, reliance on vaccination alone is not sufficient as there remain sizeable portions of the population that are not fully vaccinated. Furthermore, there remains the possibility for variants of concern (VOC) to emerge that have reduced response to vaccines and present an even greater risk of infection and morbidity. 3 Given that SARS-CoV-2 will likely remain a concern going forward in the foreseeable future, there is a need to continue identification and development of additional treatment options for this virus and any emerging variants of interest that may appear. Initially, efforts at identifying antiviral agents effective against SARS-CoV-2 focused on repurposing existing chemical libraries of approved drugs. 4,5 These efforts identified several potential therapeutics and resulted in some "hits" that have been of use, such as dexamethasone for ICU and ventilated patients, Paxlovid (orally active), and Remdesivir (iv infusion) antivirals for use in infected patients at risk of morbidity or death from severe infection. 6–8 Administration of convalescent plasma from recovered COVID-19 patients was also reported to prevent hospitalizations in a clinical tr -Abstract Truncated-

Human Cathelicidin Inhibits SARS-CoV-2 Infection: Killing Two Birds with One Stone

Upregulating Human Cathelicidin Antimicrobial Peptide LL-37 Expression May Prevent Severe COVID-19 Inflammatory Responses and Reduce Microthrombosis

Synthetic Peptides Outside the Spike Protein Heptad Repeat Regions As Potent Inhibitors of Sars-Associated Coronavirus

Inhibition of SARS-CoV-2 (previously 2019-nCoV) infection by a highly potent pan-coronavirus fusion inhibitor targeting its spike protein that harbors a high capacity to mediate membrane fusion

Cathepsin L plays a key role in SARS-CoV-2 infection in humans and humanized mice and is a promising target for new drug development

Peptidomimetic Analogues Act as Effective Inhibitors against SARS-CoV-2 by Blocking the Function of Cathepsin L

Potent prophylactic and therapeutic efficacy of recombinant human ACE2-Fc against SARS-CoV-2 infection in vivo

Peptide S4 is an entry inhibitor of SARS-CoV-2 infection

Aptamer Blocking Strategy Inhibits SARS‐CoV‐2 Virus Infection

Human Defensins Inhibit SARS-CoV-2 Infection by Blocking Viral Entry

Inhibition of SARS-CoV-2 infection in human airway epithelium with a xeno-nucleic acid aptamer

Lipid Nanoparticle-Based Inhibitors for SARS-CoV-2 Host Cell Infection

Efficacy of host cell serine protease inhibitor MM3122 against SARS-CoV-2 for treatment and prevention of COVID-19

A Novel Therapeutic Peptide Blocks SARS-CoV-2 Spike Protein Binding with Host Cell ACE2 Receptor

Inhibition of SARS-CoV-2 Infection by Human Defensin HNP1 and Retrocyclin RC-101.

Cross-linking Peptide and Repurposed Drugs Inhibit Both Entry Pathways of SARS-CoV-2

Protective Efficacy of Novel Engineered Human ACE2-Fc Fusion Protein Against Pan-SARS-CoV-2 Infection In Vitro and in Vivo

Structurally Modified Bioactive Peptide Inhibits SARS-CoV-2 Lentiviral Particles Expression

An angiotensin-converting enzyme-2-derived heptapeptide GK-7 for SARS-CoV-2 spike blockade

Lucidenic acid A inhibits the binding of hACE2 receptor with spike protein to prevent SARS-CoV-2 invasion

Human surfactant protein A inhibits SARS-CoV-2 infectivity and alleviates lung injury in a mouse infection model